0	10	Expression	expression	NN
11	13	of	of	IN
14	19	c-fos	c-fos	NN
19	20	,	,	,
21	26	c-jun	c-jun	NN
27	30	and	and	CC
31	34	jun	jun	NN
35	36	B	b	NN
37	39	in	in	IN
40	50	peripheral	peripheral	JJ
51	56	blood	blood	NN
57	68	lymphocytes	lymphocyte	NNS
69	73	from	from	IN
74	79	young	young	JJ
80	83	and	and	CC
84	91	elderly	elderly	JJ
92	98	adults	adult	NNS
98	99	.	.	.

101	104	The	the	DT
105	115	expression	expression	NN
116	118	of	of	IN
119	124	c-fos	c-fos	NN
124	125	,	,	,
126	131	c-jun	c-jun	NN
132	135	and	and	CC
136	139	jun	jun	NN
140	141	B	B	NNP
142	157	proto-oncogenes	proto-oncogene	NNS
158	161	was	be	VBD
162	169	studied	study	VBN
170	172	in	in	IN
173	191	phytohemagglutinin	phytohemagglutinin	NN
192	193	(	(	(
193	196	PHA	PHA	NNP
196	197	)	)	)
198	207	activated	activate	VBN
208	218	peripheral	peripheral	JJ
219	224	blood	blood	NN
225	236	lymphocytes	lymphocyte	NNS
237	238	(	(	(
238	241	PBL	PBL	NNP
241	242	)	)	)
243	247	from	from	IN
248	253	young	young	JJ
254	257	and	and	CC
258	262	aged	aged	JJ
263	269	humans	human	NNS
269	270	.	.	.

271	279	Specific	specific	JJ
280	285	mRNAs	mrna	NNS
286	289	for	for	IN
290	295	c-fos	c-fos	NN
296	299	and	and	CC
300	305	c-jun	c-jun	NN
306	310	were	be	VBD
311	321	detectable	detectable	JJ
322	328	within	within	IN
329	331	30	30	CD
332	335	min	min	NN
336	341	after	after	IN
342	346	cell	cell	NN
347	357	activation	activation	NN
358	361	and	and	CC
362	369	reached	reach	VBD
370	377	maximal	maximal	JJ
378	384	levels	level	NNS
385	391	within	within	IN
392	393	2	2	CD
394	395	h	h	NN
395	396	.	.	.

397	401	Both	both	CC
402	407	c-fos	c-fos	NN
408	411	and	and	CC
412	415	jun	jun	NN
416	417	B	B	NNP
418	423	mRNAs	mrna	NNS
424	433	decreased	decrease	VBD
434	436	to	to	TO
437	451	pre-activation	pre-activation	JJ
452	458	levels	level	NNS
459	465	within	within	IN
466	467	6	6	CD
468	469	h	h	NN
469	470	,	,	,
471	476	while	while	IN
477	482	c-jun	c-jun	NN
483	487	mRNA	mRNA	NNP
488	496	remained	remain	VBD
497	505	elevated	elevated	JJ
505	506	.	.	.

507	509	In	in	IN
510	523	PHA-activated	pha-activated	JJ
524	527	PBL	PBL	NNP
527	528	,	,	,
529	531	no	no	DT
532	543	age-related	age-related	JJ
544	555	differences	difference	NNS
556	560	were	be	VBD
561	569	observed	observe	VBN
570	572	in	in	IN
573	578	c-fos	c-fos	NN
579	581	or	or	CC
582	585	jun	jun	NN
586	587	B	B	NNP
588	592	mRNA	mRNA	NNP
593	603	expression	expression	NN
603	604	.	.	.

605	612	However	however	RB
612	613	,	,	,
614	619	c-jun	c-jun	NN
620	624	mRNA	mrna	NN
625	631	levels	level	NNS
632	641	decreased	decrease	VBD
642	655	significantly	significantly	RB
656	657	(	(	(
657	661	1.73	1.73	CD
662	665	+/-	+/-	SYM
666	670	0.08	0.08	CD
671	674	vs.	vs.	IN
675	679	1.16	1.16	CD
680	683	+/-	+/-	SYM
684	688	0.09	0.09	CD
689	698	arbitrary	arbitrary	JJ
699	704	units	unit	NNS
704	705	,	,	,
706	707	P	p	NN
708	709	<	<	SYM
710	714	0.01	0.01	CD
714	715	,	,	,
716	721	young	young	JJ
722	725	vs.	vs.	CC
726	729	old	old	JJ
729	730	)	)	)
731	733	in	in	IN
734	737	PBL	PBL	NNP
738	742	from	from	IN
743	750	elderly	elderly	JJ
751	762	individuals	individual	NNS
763	772	activated	activate	VBN
773	777	with	with	IN
778	781	PHA	PHA	NNP
781	782	.	.	.

783	790	Because	because	IN
791	799	previous	previous	JJ
800	804	work	work	NN
805	808	has	have	VBZ
809	821	demonstrated	demonstrate	VBN
822	826	that	that	IN
827	828	T	t	NN
829	834	cells	cell	NNS
835	839	from	from	IN
840	847	elderly	elderly	JJ
848	859	individuals	individual	NNS
860	863	may	may	MD
864	871	display	display	VB
872	878	normal	normal	JJ
879	892	proliferative	proliferative	JJ
893	902	responses	response	NNS
903	907	when	when	WRB
908	917	activated	activate	VBN
918	921	via	via	IN
922	925	the	the	DT
926	934	anti-CD2	anti-cd2	JJ
935	942	pathway	pathway	NN
942	943	,	,	,
944	949	c-jun	c-jun	NN
950	953	and	and	CC
954	957	jun	jun	NN
958	959	B	B	NNP
960	964	mRNA	mRNA	NNP
965	975	expression	expression	NN
976	979	was	be	VBD
980	984	also	also	RB
985	992	studied	study	VBN
993	995	in	in	IN
996	1014	anti-CD2-activated	anti-cd2-activated	JJ
1015	1023	purified	purify	VBN
1024	1025	T	t	NN
1026	1031	cells	cell	NNS
1031	1032	.	.	.

1033	1035	No	no	DT
1036	1047	age-related	age-related	JJ
1048	1059	differences	difference	NNS
1060	1064	were	be	VBD
1065	1070	found	find	VBN
1071	1073	in	in	IN
1074	1077	the	the	DT
1078	1088	expression	expression	NN
1089	1091	of	of	IN
1092	1098	either	either	DT
1099	1101	of	of	IN
1102	1107	these	these	DT
1108	1111	two	two	CD
1112	1127	proto-oncogenes	proto-oncogene	NNS
1128	1130	by	by	IN
1131	1139	anti-CD2	anti-cd2	JJ
1140	1149	activated	activate	VBN
1150	1151	T	t	NN
1152	1157	cells	cell	NNS
1157	1158	.	.	.

1159	1164	These	these	DT
1165	1172	results	result	NNS
1173	1180	suggest	suggest	VBP
1181	1185	that	that	IN
1186	1189	the	the	DT
1190	1199	decreased	decrease	VBN
1200	1204	IL-2	il-2	NN
1205	1215	production	production	NN
1216	1219	and	and	CC
1220	1233	proliferative	proliferative	JJ
1234	1242	response	response	NN
1243	1252	displayed	display	VBN
1253	1255	by	by	IN
1256	1269	PHA-activated	pha-activated	JJ
1270	1273	PBL	PBL	NNP
1274	1278	from	from	IN
1279	1286	elderly	elderly	JJ
1287	1293	adults	adult	NNS
1294	1297	may	may	MD
1298	1300	be	be	VB
1301	1308	related	related	JJ
1309	1311	to	to	TO
1312	1323	age-related	age-related	JJ
1324	1331	changes	change	NNS
1332	1334	in	in	IN
1335	1340	c-jun	c-jun	NN
1341	1345	mRNA	mrna	NN
1346	1356	expression	expression	NN
1357	1360	and	and	CC
1361	1363	in	in	IN
1364	1367	the	the	DT
1368	1373	ratio	ratio	NN
1374	1376	of	of	IN
1377	1382	c-fos	c-fos	NN
1383	1385	to	to	TO
1386	1391	c-jun	c-jun	NN
1392	1396	mRNA	mrna	NN
1396	1397	.	.	.